Hall Private Wealth Advisors’s Nektar Therapeutics NKTR Stock Holding History

Hall Private Wealth Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$5.96K	Buy	+667	New	+$6.42K	﹤0.01%	39

Other funds holding NKTR

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

Hall Private Wealth Advisors's NKTR Position: Q3 2023 in Review

Hall Private Wealth Advisors opened a new position in Nektar Therapeutics (NKTR) in Q3 2023: 667 shares worth $5.96K. The stake represents ﹤0.01% of the portfolio and ranks #39 among its holdings.

138 funds tracked by Wall St. Rank hold NKTR as of Q3 2023.

Hall Private Wealth Advisors held 667 shares of Nektar Therapeutics worth $5.96K as of Q3 2023.
Nektar Therapeutics was a new Hall Private Wealth Advisors position in Q3 2023.
Nektar Therapeutics made up ﹤0.01% of Hall Private Wealth Advisors's portfolio in Q3 2023, its #39 holding.
138 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2023.

Based on Hall Private Wealth Advisors's 13F filing for Q3 2023, filed 15 Nov 2023.